Wordt geladen...
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we explored factors that may lead to tivantinib resistance, especially in regards to its interaction with ATP-bind...
Bewaard in:
| Gepubliceerd in: | Cancers (Basel) |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7017082/ https://ncbi.nlm.nih.gov/pubmed/31940916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010186 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|